|
WO2021040526A1
|
|
Q-er peptide
|
|
AU2018216033A1
|
|
Peptide modulators of the interaction between human C-peptide and human elastin receptor for therapeutic use
|
|
EP2490021A1
|
|
Modulators of PRR and GPCR signalling
|
|
US2009227505A1
|
|
Methods and uses for protein breakdown products
|
|
EP2269154A1
|
|
Methods for identifying biologically active peptides and predicting their function
|
|
WO2009014440A1
|
|
Inhibition of renal ischemia reperfusion injury by synthetic oligopeptides
|
|
EP2109054A1
|
|
Methods for identifying biologically active peptides and predicting their function
|
|
EP2106791A1
|
|
Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation
|
|
AU2008215193A1
|
|
Treatment of trauma hemorrhage with short oligopeptides
|
|
US2008076714A1
|
|
Administration of gene-regulatory peptides
|
|
US2008171094A1
|
|
Treatment of burns
|
|
CN101443080A
|
|
Use of peptides for the control of radiation injury
|
|
WO2007097624A1
|
|
Pharmaceutical compositions for the treatment of influenza infections
|
|
CA2614084A1
|
|
Treatment of tumors
|
|
EP1864692A1
|
|
Use of peptides for the control of radiation injury
|
|
US2007219138A1
|
|
Compositions capable of reducing elevated blood urea concentration
|
|
US2006111292A1
|
|
Treatment of type I diabetes
|
|
AU2005205734A1
|
|
Immunoregulator
|
|
AU2005205750A1
|
|
Immunoregulator
|
|
HK1070835A1
|
|
Pharmaceutical compositions for the treatment of sars
|
